Physiological hematopoietic system

The physiological hematopoietic system is the integrated network of tissues and organs, primarily the bone marrow, spleen, and lymph nodes, dedicated to the production and regulation of blood cells. This system facilitates hematopoiesis, a highly regulated process where hematopoietic stem cells differentiate into myeloid and lymphoid lineages to produce erythrocytes, leukocytes, and platelets (StatPearls, 2023). These components are vital for oxygen transport, immune surveillance, and blood clotting. Dysregulation of the hematopoietic system is central to the pathogenesis of diseases such as leukemia, lymphoma, and various types of anemia (NIH, 2024). While the system as a whole is not a single molecular target, it is the focus of many pharmacological interventions, including colony-stimulating factors that promote cell recovery and immunosuppressants that modulate immune activity. Additionally, the system is frequently a site of off-target toxicity for many drugs, leading to adverse effects like myelosuppression (PubMed, 2014).

Other names

Hematopoietic systemBlood-forming systemHemopoietic systemHematopoiesis

Therapeutic agents modulate the hematopoietic system by binding to specific growth factor receptors (e.g., erythropoietin receptor, G-CSF receptor) to induce signal transduction pathways like JAK/STAT, which promote the survival, proliferation, and differentiation of progenitor cells (StatPearls, 2023). Conversely, many cytotoxic drugs inhibit this system by interfering with DNA replication or microtubule dynamics in rapidly dividing hematopoietic precursors, leading to myelosuppression (PubMed, 2014).